DOWNER FOR SSRI MAKERS

The multi-billion-dollar SSRI market has for years been a source of joy for drug makers working in the space. But these popular antidepressants may not be as effective as once thought, leaving SSRI patients wondering if they're on the right meds -- and pharma companies clambering for a stake in a different reuptake-inhibitor market.

Pharmaceutical Executive (http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=378218)